InMed Pharmaceuticals (INM) EPS (Weighted Average and Diluted) (2022 - 2025)
Historic EPS (Weighted Average and Diluted) for InMed Pharmaceuticals (INM) over the last 4 years, with Q4 2025 value amounting to -$0.51.
- InMed Pharmaceuticals' EPS (Weighted Average and Diluted) rose 8598.9% to -$0.51 in Q4 2025 from the same period last year, while for Dec 2025 it was -$3.32, marking a year-over-year increase of 7557.03%. This contributed to the annual value of -$8.36 for FY2025, which is 5847.58% up from last year.
- Latest data reveals that InMed Pharmaceuticals reported EPS (Weighted Average and Diluted) of -$0.51 as of Q4 2025, which was up 8598.9% from -$0.44 recorded in Q3 2025.
- InMed Pharmaceuticals' 5-year EPS (Weighted Average and Diluted) high stood at -$0.14 for Q2 2023, and its period low was -$15.24 during Q3 2023.
- Moreover, its 4-year median value for EPS (Weighted Average and Diluted) was -$3.14 (2024), whereas its average is -$3.63.
- As far as peak fluctuations go, InMed Pharmaceuticals' EPS (Weighted Average and Diluted) crashed by 256238.74% in 2024, and later skyrocketed by 8598.9% in 2025.
- InMed Pharmaceuticals' EPS (Weighted Average and Diluted) (Quarter) stood at -$6.14 in 2022, then skyrocketed by 39.58% to -$3.71 in 2023, then grew by 1.89% to -$3.64 in 2024, then surged by 85.99% to -$0.51 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$0.51 for Q4 2025, versus -$0.44 for Q3 2025 and -$1.83 for Q2 2025.